TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AJANTPHARM Stock 12 Month Forecast
There Are No Analyst Ratings for IN:AJANTPHARM In The Last 3 Months.
Highest Price Target―
Average Price Target―
Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
AJANTPHARM Financial Forecast
AJANTPHARM Earnings Forecast
Next quarter’s earnings estimate for AJANTPHARM is ₹19.34 with a range of ₹18.51 to ₹20.10. The previous quarter’s EPS was ₹20.80. AJANTPHARM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AJANTPHARM has Performed in-line its overall industry.
Next quarter’s earnings estimate for AJANTPHARM is ₹19.34 with a range of ₹18.51 to ₹20.10. The previous quarter’s EPS was ₹20.80. AJANTPHARM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AJANTPHARM has Performed in-line its overall industry.
AJANTPHARM Sales Forecast
Next quarter’s sales forecast for AJANTPHARM is ₹13.12B with a range of ₹12.80B to ₹13.31B. The previous quarter’s sales results were ₹13.54B. AJANTPHARM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AJANTPHARM has Performed in-line its overall industry.
Next quarter’s sales forecast for AJANTPHARM is ₹13.12B with a range of ₹12.80B to ₹13.31B. The previous quarter’s sales results were ₹13.54B. AJANTPHARM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AJANTPHARM has Performed in-line its overall industry.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Param Desai
Prabhudas Lilladher
Not Ranked
Prabhudas Lilladher
₹3,200
Buy
9.56%
Upside
Initiated
09/19/25
Ajanta Pharma Limited (AJANTPHARM) Has a New Rating from Prabhudas Lilladher
Ajanta Pharma (AJP:IN) PT Raised to INR3,140 at JefferiesJefferies analyst Alok Dalal raised the price target on Ajanta Pharma (AJP:IN) to INR3,140.00 (from INR2,850.00) while maintaining a Buy rating.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Param Desai
Prabhudas Lilladher
Not Ranked
Prabhudas Lilladher
₹3,200
Buy
9.56%
Upside
Initiated
09/19/25
Ajanta Pharma Limited (AJANTPHARM) Has a New Rating from Prabhudas Lilladher
Ajanta Pharma (AJP:IN) PT Raised to INR3,140 at JefferiesJefferies analyst Alok Dalal raised the price target on Ajanta Pharma (AJP:IN) to INR3,140.00 (from INR2,850.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +2.30% per trade.
Copying Alok Dalal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.60% per trade.
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +12.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AJANTPHARM Analyst Recommendation Trends
Rating
Apr 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
0
Buy
2
4
7
6
Hold
0
0
0
0
Sell
0
0
0
0
Strong Sell
0
0
0
0
total
2
4
7
6
In the current month, AJANTPHARM has received 6Buy Ratings, 0Hold Ratings, and 0Sell Ratings. AJANTPHARM average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
AJANTPHARM Stock Forecast FAQ
What is IN:AJANTPHARM’s average 12-month price target, according to analysts?
Currently, no data Available
What is IN:AJANTPHARM’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IN:AJANTPHARM, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Ajanta Pharma Limited a Buy, Sell or Hold?
Currently, no data Available
What is Ajanta Pharma Limited’s share price target?
Currently, no data Available
What do analysts say about Ajanta Pharma Limited?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of Ajanta Pharma Limited?
To buy shares of IN:AJANTPHARM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.